Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health. So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
Seizures & Epilepsy: How Cell Phone Videos Could be an Effective Tool
9.3.2023Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Selim Benbadis, MD It may be challenging for a family member to take a video on their cell phone while a patient is having a seizure. However, they have been deemed useful in helping physicians establish a history of seizures in epileptic patients. So should clinicians consider this as a reimbursable diagnostic tool? Joined by the physician who posed this question in a recent article for the journal Neurology Clinical Practice, Dr. Andrew Wilner speaks with Dr. Selim Benbadis, Professor of Neurology and the Director of the Comprehensive Epilepsy Program at the University of South Florida.
Keys to Slowing Disease Progression in SMA
28.2.2023Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John F. Brandsema, MD Spinal muscular atrophy (SMA) is a rapidly progressive disease, but current treatment options might help us slow its progression. Dr. Charles Turck explores these treatment options with Dr. John Brandsema from the Perelman School of Medicine at the University of Pennsylvania.
Verpasse keine Episode von “NeuroFrontiers” und abonniere ihn in der kostenlosen GetPodcast App.
Examining Care Collaborations for Patients with SMA
28.2.2023Host: Andrew Wilner, MD, FACP, FAAN Guest: Nassim Rad, MD Guest: Vanessa Battista, RN Collaborative care plays an important role in treating patients is spinal muscular dystrophy (SMA). To learn more about this, Dr. Andrew N. Wilner is joined by Drs. Vanessa Battista and Nassim Rad to share their insights on team structures and collaborative care for SMA.
A Look at Lecanemab: The Latest Breakthrough in Alzheimer’s Treatment
22.2.2023Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: David Weisman, MD Alzheimer’s disease is the most common form of dementia, and symptoms become more severe over time. In fact, it’s the leading cause of disability and poor health in older adults. And although there’s no cure, a new medication called lecanemab recently received accelerated approval by the US Food and Drug Administration. So what might this new development mean for the 6 million Americans living with this debilitating disease? Find out as Dr. Andrew Wilner speaks with fellow ReachMD host Dr. David Weisman, who’s also the Director of Clinical Research at Abington Neurological Associates.
First Responders with PTSD: Exploring the Neurological Underpinnings
25.1.2023Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Marilyn J. Wooley PhD Due to the nature of their work, first responders may be at a higher risk for developing posttraumatic stress disorder (PTSD). So how can clinicians help their front-line patients with PTSD? Dr. Andrew Wilner will discuss this with Dr. Marilyn Wooley, Clinical Psychologist who specializes in treating first responders and author of the book, How Heroes Heal: Stories of First Responders and the Journey from Posttraumatic Stress Injury to Posttraumatic Growth.
Childhood-Onset Epilepsy: A Look into the Effects of Aging
29.12.2022Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Bruce Hermann, PhD Guest: Shlomo Shinnar, M.D., Ph.D. In hopes of learning more about how the brain changes due to aging in patients with childhood-onset epilepsy, a new study was funded that may suggest some interesting findings. So what do we need to know from the results of this study? To dive into this topic, Dr. Andrew Wilner is joined by Dr. Bruce Hermann, Emeritus Professor at the University of Wisconsin School of Medicine and Public Health, and Dr. Shlomo Shinnar, Professor Emeritus of Neurology and Pediatrics at Albert Einstein College of Medicine.
The Impact of Individual Autonomic Domains in Parkinson’s Disease
20.12.2022Host: Jerome Lisk, MD Guest: Katherine Longardner, MD A recent five-year observational study aimed to determine the impact of individual autonomic domains that were associated with Parkinson’s disease. So what were the key findings of this study? Join Dr. Jerome Lisk as he welcomes Dr. Katherine Longardner, Assistant Professor of Neurosciences at UC San Diego Health, to discuss this trial in-depth.
Understanding MRI: Common Challenges and Expert Guidance for MS Diagnosis
19.12.2022Host: Jason Freeman, MD, MBA Guest: James Stankiewicz, MD Guest: Stephen Yeung, DO Magnetic resonance imaging (MRI) is an important tool for diagnosing multiple sclerosis (MS) and has been part of the diagnostic criteria for more than 20 years. But potential challenges can arise when reading an MRI scan, which can lead to a misdiagnosis. That’s why Drs. Stephen Yeung and James Stankiewicz join Dr. Jason Freeman to share best practices for understanding MRI scans for more accurate MS diagnosis. 246866 10/22
The Role of TAAR1 in Treating Neuropsychiatric Disorders
30.11.2022Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Craig Chepke, MD, FAPA Trace amine-associated receptor type 1 (TAAR1) is thought to be the most important receptor for treating neuropsychiatric disorders, and it could provide more benefits and medications to patients with these illnesses. To discover more, Dr. Charles Turck, is joined by Dr. Craig Chepke, Clinical Assistant Professor of Psychiatry at SUNY Upstate Medical University.
Treating Psychosis in Schizophrenia: Could a Non-D2-Receptor Binding Drug Be the Key?
23.11.2022Guest: Matt Birnholz, MD Could an oral compound represent a new class of psychotropic agent with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia? That’s what the authors of a recent study wanted to find out, and it’s what Dr. Matt Birnholz explores in this Audio Abstract. To review the full abstract, please click here.